IRADIMED CORP(IRMD)— Stock Profile, AI Score & Financials
Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated .
IRADIMED CORP (IRMD) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores IRMD at 63.5/100 on a 32-signal composite quality model, placing it at rank #615 of 2,962 stocks — the top 25% of the AI-ranked universe. IRMD scores in the top quartile across balance sheet strength (96.4), profitability (85.5), free cash flow (83.2). Areas of concern include revenue scale (13.8) and institutional flow (39.4), which score below median versus the broader universe. Shareholder dilution risk is elevated at 30.1/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), IRADIMED CORP reports quarterly revenue of $20.5M, net income of $5.2M, an operating margin of 31.2%. Top institutional holders of IRMD by reported 13-F value include BlackRock, KAYNE ANDERSON RUDNICK INVESTMENT MANAGEMENT, RENAISSANCE TECHNOLOGIES, based on the most recent SEC filings. IRMD trades on the Nasdaq exchange and files with the SEC under CIK 1325618. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate IRMD daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for IRADIMED CORP directly from SEC EDGAR.
AI Quality Score
63.5/100
AI Rank
#615
Revenue
$20.5M
Net Income
$5.2M
Free Cash Flow
$5.8M
Operating Margin
31.2%
IRMD key financials by period
IRADIMED CORP reported revenue, net income and margins by fiscal period, from SEC filings.
Period
Form
Revenue
Net income
Operating margin
FY 2025
10-K
$83.8M
$22.5M
31.2%
FY 2024
10-K/A
$73.2M
$19.2M
30.0%
FY 2023
10-K/A
$65.6M
$17.2M
30.6%
FY 2022
10-K
$53.3M
$12.8M
29.3%
FY 2021
10-K
$41.8M
$9.3M
23.5%
FY 2020
10-K
$31.7M
$1.4M
-2.4%
Institutions holding IRMD
Institutional investors reporting a position in IRADIMED CORP on SEC Form 13F.
AI-extracted from the 10-Q filed 2026-07-31 — Q2 FY2026 (quarter ended June 30, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.
Revenue was essentially flat at $20.5M (+0.5% YoY), but net income fell to $5.2M as gross margin compressed to 74% from 78% on production inefficiencies tied to the new MRidium 3870 pump.
Biggest Revenue Drivers
Devices$13.8M-5% YoY
Decline driven by lower IV infusion pump systems revenue, partially offset by higher patient vital signs monitoring and ferro magnetic detection sales
Disposables$4.8M+14% YoY
Increase attributed in part to modifications to the sales incentive plan
Biggest Revenue Drivers
Total revenue: $20.5M+0.5% YoY
Devices$13.8M-5% YoY
Decline driven by lower IV infusion pump systems revenue, partially offset by higher patient vital signs monitoring and ferro magnetic detection sales
Within Devices
IV Infusion Pump Systems$6.4M-21% YoY
Disposables$4.8M+14% YoY
Increase attributed in part to modifications to the sales incentive plan
Services and other$1.1M+7% YoY
Amortization of extended maintenance agreements$0.8M+28% YoY
Largest Expense Items
Cost of revenue$5.3M+18% YoY
Increase attributed to initial production inefficiencies on new product manufacturing
Sales and marketing$4.2M+6% YoY
Increased sales commissions related to monitor bookings and newly released MRidium 3870 pump bookings
General and administrative$3.9M-9% YoY
Lower legal and professional expenses, regulatory consulting, and payroll and benefit expenses
Research and development$0.7M-22% YoY
Decrease in payroll and benefit expenses capitalized as internal software development for the period
Margins: Gross margin fell to 74% from 78% YoY due to initial production inefficiencies on new product manufacturing; operating margin also declined to 31.3% from 33.3% as gross profit dropped despite lower opex-to-revenue ratio.
Watch Items from the Filing
Gross margin compressed to 74% from 78% YoY due to initial production inefficiencies on new product manufacturing.
US revenue fell 8% YoY to $16.7M while international revenue grew 69% to $3.7M; domestic mix dropped to 82% of revenue from 89%.
IV infusion pump systems revenue declined 21% YoY to $6.4M even as the new MRidium 3870 pump ramps, while vital signs monitoring grew 12%.
Board declared a subsequent quarterly cash dividend of $0.20/share, payable August 28, 2026, continuing the capital return program.
AI-extracted and verified against SEC EDGAR filing text. Not investment advice.
